... WhatsApp

Heart Risks Compared: Two Common Prostate Cancer Drugs

You are here >> Home > Latest Updates > Prostate Cancer > Heart Risks…

Heart Risks Compared: Two Common Prostate Cancer Drugs

Men with advanced prostate cancer often receive hormone-based treatments to help slow the disease. Two common medicines are abiraterone acetate (AA) and enzalutamide (ENZA). But do they have different risks for heart problems?

This study looked at real-world data from over 1,300 men with metastatic castration-resistant prostate cancer. About 550 were treated with AA, and 800 received ENZA.

Researchers found that men who took abiraterone had a 65% higher risk of serious heart problems, like heart attacks or strokes, compared to those who took enzalutamide.

One possible reason is that abiraterone is usually given with steroids, which can affect blood pressure, blood sugar, and the heart over time. In this study, men on abiraterone spent much more time on steroid-based treatments—almost 300 days compared to just 72 days for those on enzalutamide.

This doesn’t mean abiraterone is unsafe, but it does show that heart health should be considered when choosing a treatment, especially for men who already have heart disease or diabetes.

Better communication between primary care and hospital doctors is also important, as the study found that some health conditions were not always recorded the same way in different care settings.

Talk to your doctor about your heart health and which prostate cancer treatment is safest for you.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.